The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family
that is abnormally activated in many epithelial tumors. Receptor activation leads to …

Identification of the key roles of protein kinases in cancer has led to extensive efforts to
develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 …

Progress in identifying and understanding the molecular and cellular causes of cancer has
led to the discovery of anomalies that characterize cancer cells and that represent targets for …

Purpose: The epidermal growth factor receptor (EGFR) is a mediator of squamous cell
carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active …

Despite aggressive surgical and chemotherapeutic interventions, non-small-cell lung cancer
(NSCLC) is the leading cause of cancer-related death in men and women with overall cure …

The varying efficacy and toxicity of traditional cancer therapies has driven the development
of novel target-based agents. Members of the HER (Human Epidermal Receptor) family, in …

Fifteen% or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …

The epidermal growth factor receptor (EGFR) is widely expressed in advanced colorectal
cancers (CRCs), and higher levels of EGFR are inversely related to survival in these …

It is well known that growth factors play an important role in normal cell proliferation by
means of stimulation of growth factor receptors located on the surface of cells. Tumor cells …

There is an increased perception that current chemotherapeutic drugs have almost reached
a ceiling as systemic anticancer therapies. In great part because of their unpredictable side …